The Global report "Cell Culture Market in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $51.3 billion by 2028, growing at a CAGR of 12.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by government support and funding for cell-based research and emerging cell culture technologies for cell-based vaccines. Further, the demand for 3D over 2D cell cultures is creating opportunities the growth of this market.
The cell culture industry is expected to experience strong growth in the near future as advances in biotechnology, stem cell research, and tissue engineering continue to progress. The growth of the cell culture market is driven by increased demand for cell culture-based products and services across various industries. Additionally, the development of new technologies and the emergence of innovative product offerings have further strengthened the market's growth potential. Cell culture technologies are now being used in a variety of industries, including biopharmaceuticals, regenerative medicine, diagnostics, and research and development. The increasing use of cell culture in these industries has enabled the market to grow significantly. In the coming years, the cell culture market is expected to experience further growth as the demand for cell culture-based products and services continues to increase. Moreover, the development of new technologies, such as 3D bioprinting and organ-on-chip systems, is likely to further drive the market's growth.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559
Browse in-depth TOC on "Cell Culture Market"
692 - Tables
42 - Figures
556 - Pages
Key Market Players:
The global cell culture market is a consolidated market, with Thermo Fisher Scientific (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US) together accounting for ~70–75% of the global market.
DRIVER: Adoption of single-use technologies
Over the last few years, biopharmaceutical manufacturers have increasingly adopted single-use technologies (SUTs). These SUTs have helped comply with stringent regulations and control costs through multiple benefits. Some single-use bioreactors (SUBs) have low operating volume requirements; this allows for more flexibility in production volumes scaled up over time, depending on the demand. Also, SUTs reduce cross-contamination risk, facilitating rapid changeovers and multiple production batches. SUTs also require less space than multiple-use bioreactors, less capital investment, and less sterilization for storage. This reduces the overall operating and maintenance costs and the environmental impact of these operations. The advantages of SUTs have fueled their adoption in the biopharmaceutical sector, thus driving the growth of the overall market during the forecast period.
RESTRAINT: Limitations in producing high-density cell cultures
Although the adoption of advanced technologies such as microcarriers is increasing in high-density cell cultures, there are several limitations associated with their use, which makes the process of cell culture very laborious and expensive. Some of them are: Agitation is required in a stirred-tank bioreactor to make a homogenous cell culture system. Fluid turbulence damages cells and results in cell debris formation and low cell yield, thus increasing downstream processing costs. The number of microcarriers needs to be increased for higher culture density. This, however, leads to a higher degree of collisions (bead-to-bead or microcarrier-bound-cells to mechanical impeller), resulting in cell death and decreased cell yield.
OPPORTUNITY: Growth hotspots in emerging economies
Developing countries such as China, India, and other countries in the Asia Pacific are expected to offer significant growth opportunities for players operating in the market. The booming biopharmaceutical sector in these countries, increased risk of pandemics (such as swine flu and COVID-19), less-stringent regulatory guidelines, and the low manufacturing cost advantage are the major factors attracting market players to set up and expand their presence in these countries.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=559
Cell Culture Market Dynamics:
Drivers:
- Government support and funding for cell-based research
- Emerging cell culture technologies for cell-based vaccines
- Growing popularity of monoclonal antibodies
- Adoption of single-use technologies
- Growing focus on product development
- Growth in cell and gene therapies and stem cell research
- Incidence of infectious diseases
Restraints:
- High cost of cell biology research
- Limitations in producing high-density cell cultures
Opportunities:
- Demand for 3D over 2D cell cultures
- Growth hotspots in emerging economies
Challenges:
- Disposal of plastic consumables
The North America region catered the largest share of the cell culture market in 2022.
The growing regulatory approvals for and awareness of cell culture-based vaccines, rising investments in biopharmaceutical R&D coupled with various initiatives from the leading companies, and conferences and symposia that create awareness of the latest cell culture trends are the key factors driving the growth of the cell culture market in North America. Biopharmaceutical companies in North America focus on R&D activities to develop and commercialize novel drugs and therapies. Additionally, various initiatives from leading companies have accelerated growth in North America.
Key players in the cell culture market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).
Recent Developments
- In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the US.
- In October 2022, Cytiva acquired Cevec Pharmaceuticals GmbH, which is expected to strengthen Cytiva's leading position in biomanufacturing solutions.
Cell Culture Market Advantages:
- Cell culture technology can be used to develop new medicines and treatments, which can reduce the time and cost of traditional drug development.
- It is a more efficient and effective way of producing large quantities of cells for research, clinical and industrial purposes.
- It provides a platform for better understanding of cellular processes, which can lead to the development of more effective treatments.
- It enables the production of specific cell types, which can be used to study diseases and develop treatments.
- It can be used to produce cells that would be difficult to obtain through traditional means.
- It can reduce the need for animals in research and development.
- It can be used to produce stem cells for research and therapeutic purposes.
- It is a cost-effective way of producing cells for research and commercial applications.
Report Link: Cell Culture Market
Table of Content:
1 INTRODUCTION (Page No. - 67)
- STUDY OBJECTIVES
- MARKET DEFINITION
- MARKET SCOPE
- YEARS CONSIDERED
- CURRENCY CONSIDERED
- LIMITATIONS
- STAKEHOLDERS
- RESEARCH METHODOLOGY (Page No. - 72)
- RESEARCH DATA
- CELL CULTURE INDUSTRY ESTIMATION METHODOLOGY
- MARKET GROWTH RATE PROJECTIONS
- DATA TRIANGULATION
- RESEARCH ASSUMPTIONS
- RISK ANALYSIS
- EXECUTIVE SUMMARY (Page No. - 83)
- PREMIUM INSIGHTS (Page No. - 87)
- CELL CULTURE MARKET OVERVIEW
- NORTH AMERICA: CELL CULTURE INDUSTRY, BY PRODUCT AND COUNTRY (2022)
- CELL CULTURE INDUSTRY SHARE, BY APPLICATION, 2023 VS. 2028
- CELL CULTURE INDUSTRY SHARE, BY END USER, 2022 (USD MILLION)
- CELL CULTURE INDUSTRY: REGIONAL GROWTH OPPORTUNITIES
- MARKET OVERVIEW (Page No. - 90)
- INTRODUCTION
- MARKET DYNAMICS
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek